Barriers to CAR-T Access in Medicare
Examining reimbursement, timing, and site-of-care factors
influencing CAR-T access
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
Key Findings include:
- Approximately 10% of clinically eligible Medicare patients receive CAR-T therapy, reflecting non-clinical barriers to access
- Prolonged time to treatment is associated with reduced eligibility and poorer outcomes, underscoring the importance of earlier identification and referral
- CMS reimbursement structures and limited outpatient pathways constrain access to CAR-T care
Download the full paper to explore evidence-based insights into CAR-T access considerations and policy, reimbursement, and care-delivery strategies to support broader adoption.
